tiprankstipranks
Advertisement
Advertisement

EYPT Stock Latest News

EyePoint’s CAPRI Phase 3 Trial Targets Long-Acting Relief in Diabetic Eye Disease
Company AnnouncementsEyePoint’s CAPRI Phase 3 Trial Targets Long-Acting Relief in Diabetic Eye Disease
3d ago
EYPT
EyePoint Pharma Bets Big on DURAVYU Pivotal Data
PremiumCompany Announcements
EyePoint Pharma Bets Big on DURAVYU Pivotal Data
17d ago
EYPT
EyePoint receives positive DSMC recommendation for Duravyu Phase 3 trials
PremiumThe Fly
EyePoint receives positive DSMC recommendation for Duravyu Phase 3 trials
23d ago
EYPT
EyePoint Advances DURAVYU Phase 3 Wet AMD Program
PremiumCompany Announcements
EyePoint Advances DURAVYU Phase 3 Wet AMD Program
23d ago
8K
EYPT
EyePoint Pharma Bets on DURAVYU Amid Mounting Losses
PremiumCompany Announcements
EyePoint Pharma Bets on DURAVYU Amid Mounting Losses
29d ago
EYPT
Yi Chen Reiterates Buy on EyePoint Pharmaceuticals, Maintains $30 Price Target on DURAVYU Late-Stage Progress
PremiumRatingsYi Chen Reiterates Buy on EyePoint Pharmaceuticals, Maintains $30 Price Target on DURAVYU Late-Stage Progress
1M ago
EYPT
EyePoint reports Q1 EPS (99c), consensus (81c)
Premium
The Fly
EyePoint reports Q1 EPS (99c), consensus (81c)
1M ago
EYPT
EYPT Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
EYPT Upcoming Earnings Report: What to Expect?
1M ago
EYPT
Insiders Dump Shares in Global-e, EyePoint, Immunovant, Nerdy, Argan
PremiumWeekend Updates
Insiders Dump Shares in Global-e, EyePoint, Immunovant, Nerdy, Argan
1M ago
AGX
EYPT
EyePoint Highlights DURAVYU Phase 3 Progress and Cash Runway
PremiumCompany Announcements
EyePoint Highlights DURAVYU Phase 3 Progress and Cash Runway
2M ago
8K
EYPT
EyePoint Sues Ocular Therapeutix Over Alleged Defamation
PremiumCompany Announcements
EyePoint Sues Ocular Therapeutix Over Alleged Defamation
3M ago
8K
EYPT
EyePoint’s COMO Phase 3 Trial Puts Long-Acting DME Strategy in Focus
PremiumCompany Announcements
EyePoint’s COMO Phase 3 Trial Puts Long-Acting DME Strategy in Focus
3M ago
EYPT
EyePoint reports inducement grants under NASDAQ listing rule
PremiumThe FlyEyePoint reports inducement grants under NASDAQ listing rule
3M ago
EYPT
EyePoint Pharmaceuticals: Strong Clinical Momentum, Favorable Risk‑Reward, and Catalyst‑Rich Path to Duravyu Approval Support Buy Rating
Premium
Ratings
EyePoint Pharmaceuticals: Strong Clinical Momentum, Favorable Risk‑Reward, and Catalyst‑Rich Path to Duravyu Approval Support Buy Rating
3M ago
EYPT
EyePoint price target raised to $35 from $31 at Citi
Premium
The Fly
EyePoint price target raised to $35 from $31 at Citi
3M ago
EYPT
EyePoint Pharma Bets Big on DuraVu in Pivotal Push
PremiumCompany Announcements
EyePoint Pharma Bets Big on DuraVu in Pivotal Push
3M ago
EYPT
EyePoint price target raised to $30 from $23 at H.C. Wainwright
PremiumThe Fly
EyePoint price target raised to $30 from $23 at H.C. Wainwright
3M ago
EYPT
EyePoint price target raised to $29 from $27 at Chardan
PremiumThe Fly
EyePoint price target raised to $29 from $27 at Chardan
3M ago
EYPT
EyePoint reports Q4 EPS (81c), consensus (75c)
PremiumThe Fly
EyePoint reports Q4 EPS (81c), consensus (75c)
3M ago
EYPT
EyePoint expects cash to fund operations into Q4 2027
PremiumThe FlyEyePoint expects cash to fund operations into Q4 2027
3M ago
EYPT
EyePoint Starts Global Phase 3 Trials for DURAVYU
Premium
Company Announcements
EyePoint Starts Global Phase 3 Trials for DURAVYU
3M ago
8K
EYPT
EyePoint announces first patients dosed in Global Phase 3 trials of DURAVYU
Premium
The Fly
EyePoint announces first patients dosed in Global Phase 3 trials of DURAVYU
3M ago
EYPT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >